Core Viewpoint - PetMed Express, Inc. is currently unable to file its Form 10-K for the fiscal year ended March 31, 2025, due to ongoing investigations related to revenue recognition and customer complaints, but does not expect a material impact on its preliminary financial results [2]. Company Update - The Company filed a Form 12b-25 on June 16, 2025, indicating it would not meet the deadline for the 2025 Form 10-K filing [2]. - The Audit Committee is investigating anonymous reports regarding revenue recognition timing for autoship orders, a $50 coupon promotion, and the Company's culture and control environment [2]. - External legal counsel has been engaged for the investigation, which is ongoing with no conclusions reached yet [2]. - Despite the investigation, the Company believes it will not materially affect its previously announced preliminary financial results for the fourth quarter and fiscal year ended March 31, 2025 [2]. Company Background - PetMed Express, Inc. was founded in 1996 and is a pioneer in the direct-to-consumer pet healthcare sector [3]. - The Company operates as a national online pharmacy licensed across all 50 states, offering a range of pet health solutions including pharmaceuticals and OTC supplements [3]. - PetMeds aims to empower pet owners to enhance the health and wellness of their pets [3].

Core Viewpoint - PetMed Express, Inc. has announced preliminary financial results for the fourth quarter and fiscal year 2025, indicating a significant decline in net sales and an increase in net loss compared to the previous year [1][2][3]. Financial Performance - For the fiscal fourth quarter ended March 31, 2025, net sales are estimated to be between $51.1 million and $53.1 million, down from $66.5 million in the prior year [2]. - The estimated net loss for the fourth quarter is between $9.9 million and $10.4 million, compared to a net loss of $5.0 million in the prior year [2]. - For the fiscal year ended March 31, 2025, net sales are estimated to range from $231.6 million to $233.6 million, a decrease from $281.1 million in the prior year [3]. - The estimated net loss for the fiscal year is between $4.5 million and $5.0 million, an improvement from a net loss of $7.5 million in the prior year [3]. - The net loss includes a tax expense impact of $6.4 million due to a valuation allowance on the Company's net deferred tax assets [2][3]. Cash Position - As of March 31, 2025, the Company reported $54.7 million in cash and no debt [4]. Filing Status - The Company has filed Form 12b-25 with the SEC, indicating it is unable to file its Annual Report on Form 10-K within the prescribed time period, but expects to do so by July 1, 2025 [1][5].

Core Viewpoint - PetMed Express, Inc. will hold a conference call to discuss its financial results for the fourth quarter and full fiscal year ended March 31, 2025, on June 10, 2025 [1][2]. Company Overview - PetMed Express, Inc., operating as PetMeds, is a pioneer in the direct-to-consumer pet healthcare sector, founded in 1996 [3]. - The company is a licensed national online pharmacy across all 50 states, providing a range of pet health solutions including pharmaceuticals, compounded medications, and OTC supplements [3]. - PetMeds aims to empower pet owners to enhance the health and longevity of their pets through value, convenience, and care [3]. Conference Call Details - The conference call is scheduled for June 10, 2025, at 4:30 PM Eastern Time, with a question-and-answer session following the management's presentation [2]. - Participants are encouraged to dial in 5-10 minutes prior to the start time using the provided U.S. and international numbers [2]. - A telephonic replay of the conference call will be available after 7:30 PM Eastern Time on the same day until June 24, 2025 [2][3].